- FlexFactory platform for oligonucleotides, an integrated
solution to boost efficiency and speed of pharmaceutical
manufacturing to meet market demand
SHANGHAI, May 10, 2024
/PRNewswire/ -- Ribobay Pharma, a leading Chinese biopharmaceutical
contract research, development, and manufacturing organization
(CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, will provide cGMP-level
oligonucleotide (oligo) CRDMO services to the world using
Cytiva's first FlexFactory platform for oligo manufacturing.
It is scheduled to commence manufacturing in June and expects to
produce several hundred kilograms of pharmaceutical oligo per year,
bringing increased reliability, speed, and efficiency to the
development of novel therapies.
Jingui Yong, General Manager
of Ribobay Pharma, says: "With the support of Cytiva, we
will rapidly expand our oligo CRDMO business by manufacturing
high-quality and diversified innovative drugs, as well as new
vaccine adjuvant (CpG-ODNs) for global customers. We look forward
to building on synergies and creating more value with our
collaborators."
With the FlexFactory platform, Ribobay Pharma can better serve
their customers, providing process development support,
optimization, method development, pilot production services, and
customized manufacturing services.
Allen Li, President of Cytiva
in China, says: "It's an honor
to work with Ribobay Pharma to roll out our very first FlexFactory
platform for oligos. We will continue facilitating more Chinese
companies to navigate the global market, and ultimately help
improve the accessibility of life-changing therapies for global
patients."
Due to its rapid development cycle, impressive success rate, low
side effects, and lasting effectiveness, oligo drugs are now being
applied far beyond rare diseases. They're tackling chronic
conditions like hyperlipidemia, hepatitis B, and diabetes, with
over 1500 research pipelines around the globe.
However, turning oligo drugs into commercially available
products requires technology accumulation and validation,
presenting high barriers in quality control and production
processes. Due to the lack of industrialization and factory
construction experience, large-scale production faces considerable
challenges.
The collaboration between Cytiva and Ribobay Pharma is an agile
response to market needs and developmental bottlenecks. Cytiva
provides Ribobay Pharma with one-stop integrated
services, from factory design to equipment and technologies
that enable cGMP manufacturing.
Learn more about Cytiva's FlexFactory platform.
FlexFactory is a trademark of Global Life Sciences Solutions
USA LL or an affiliate doing
business as Cytiva. © 2020-2024 Cytiva.
About Cytiva
At Cytiva, our mission is to advance and accelerate the
development of therapeutics. With nearly 15 000 associates in more
than 40 countries, we're driven to use our expertise and talent to
achieve better flexibility, capacity, and efficiency for our
customers. Our broad and deep portfolio of tools and technologies,
global scale, and best-in-class service provides critical support
from discovery to delivery, for customers spanning researchers,
emerging biotech, large-scale biopharma and contract
manufacturers.
Please visit https://cytiva.com for more information.
About Ribobay Pharma
Ribobay Pharma (Anhui) Co.,
Ltd. was established in August 2021
as the spin-off company of General Biol (Anhui) Co., Ltd. which has been providing a
full range of solutions and raw materials to the global biomedical
industry for a decade. Focusing on the CXO field of therapeutic
oligonucleotides, Ribobay Pharma provides one-stop CRDMO services
to global institutes for oligo drug development and
commercialization. Please visit http://www.ribobay.com/en/ for more
information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ribobay-pharma-boosts-crdmo-offerings-with-cytivas-first-flexfactory-platform-for-oligonucleotides-302142246.html
SOURCE Cytiva